Our Story

Founded at the intersection of technology expertise and personal experience with rare cancer care, our organization was created to address the critical gaps between available genomic technologies and their clinical application in underserved patient populations.

The catalyst for our work came from witnessing firsthand how little structured data exists for rare cancers like osteosarcoma, and how this scarcity leaves families navigating complex treatment decisions without the evidence-based guidance available for more common malignancies. This experience revealed a fundamental challenge: while genomic medicine has revolutionized cancer care broadly, rare cancer patients often remain excluded from these advances due to small sample sizes and fragmented research efforts.

Our unique position, combining deep technology expertise with intimate understanding of healthcare challenges, positions us to bridge the gap between AI innovation and clinical reality. We understand both the immense potential of artificial intelligence and the rigorous validation required for healthcare applications.

Our Mission

We aim to develop AI-driven research infrastructure to accelerate discovery and improve outcomes for rare cancer patients. Our mission is to create open, collaborative platforms that serve the public interest while advancing the frontiers of precision oncology.

Our vision extends beyond building technology tools. We plan to establish new paradigms for rare disease research that leverage distributed data, privacy-preserving computation, and collaborative governance to generate insights that would be impossible for any single institution to achieve alone.

Our Values

Innovation with Purpose

We will harness cutting-edge AI and genomic technologies to solve real clinical problems, not to chase technological trends. Every platform we develop will address a genuine unmet need identified through direct engagement with patients, families, and healthcare providers. We will measure success not by technical sophistication alone, but by meaningful improvement in patient outcomes and clinical decision-making.

Scientific Rigor

Every platform we develop will undergo comprehensive validation and follow evidence-based development principles. We believe that the stakes in healthcare AI demand the highest standards of statistical validation, clinical testing, and regulatory compliance. Our work will be grounded in peer-reviewed research, transparent methodologies, and systematic approaches to bias detection and mitigation.

Accessibility

Our solutions will be designed as public infrastructure, ensuring universal access regardless of institutional resources or geographic location. We reject models that create additional barriers for patients or healthcare providers. Instead, we will build platforms that strengthen healthcare systems and expand access to precision medicine for underserved populations.

Transparency

We embrace open science principles, planning to share our methodologies and findings to benefit the broader research community. Our planned approach includes open-source software components, published algorithms, reproducible research frameworks, and public reporting of platform performance. We believe that advancing rare cancer care requires collective effort and knowledge sharing.

Our Planned Approach to Rare Cancer Research

Federated Learning and Privacy Preservation

We recognize that rare cancer research requires collaboration across institutions while maintaining strict data privacy and security. Our planned platforms will use federated learning approaches that enable analysis of distributed datasets without compromising patient confidentiality or institutional data sovereignty.

Clinical Co-Design

Rather than developing technology solutions in isolation, we plan to work directly with oncologists, nurses, patients, and families to understand real clinical workflows and decision-making processes. This co-design approach will ensure that our platforms enhance rather than disrupt existing care processes.

Regulatory Alignment

From the earliest stages of development, we will design our platforms to meet regulatory requirements for medical devices and clinical decision support systems. This proactive approach will ensure that our solutions can successfully transition from research tools to clinically deployed platforms.

Sustainable Impact

We will build platforms designed for long-term sustainability through public infrastructure models rather than commercial licensing. This approach will ensure that advances in rare cancer care remain accessible to all patients and healthcare providers regardless of their institutional resources.

Current Initiative and Future Vision

Our planned work will center on the Accuratus OncoAI (AOAI) Platform for adolescent and young adult osteosarcoma care. This comprehensive 8-year development program will serve as both a direct contribution to osteosarcoma treatment and a proof-of-concept for our broader approach to rare cancer AI research.

The methodologies, governance frameworks, and technical infrastructure we plan to develop through AOAI will establish a foundation for addressing other rare cancers where traditional research approaches have been limited by small sample sizes and data fragmentation.

Our Long-Term Vision Includes:

• Methodology Transfer: Adapting AOAI approaches to other rare cancer types

• International Expansion: Establishing collaborative frameworks for global rare cancer research

• Policy Development: Contributing to evolving governance frameworks for AI in healthcare

• Capacity Building: Training researchers and clinicians in federated rare disease research methodologies

Recognition & Accountability

We understand that our planned work will address some of the most challenging problems in healthcare, affecting families during their most vulnerable moments. This responsibility drives our commitment to transparency, rigorous validation, and ethical development practices.

We will be accountable not only to our funding partners and collaborating institutions, but to the rare cancer community we plan to serve. Every decision we make will be guided by the knowledge that behind every data point is a young person fighting for their future, and a family hoping for better answers than exist today.

Join Our Mission

Whether you're a healthcare professional interested in rare cancer research, a technology expert passionate about healthcare applications, a funding organization focused on health innovation, or a patient advocate working to improve rare cancer care, we welcome collaboration with individuals and organizations who share our commitment to advancing precision medicine for underserved populations.

Our success will depend on collective effort, shared expertise, and sustained commitment to improving outcomes for rare cancer patients across Canada and beyond. We are actively seeking partners, collaborators, and supporters who can help turn this vision into reality.